Elite Pharmaceuticals Inc
OTC:ELTP
Elite Pharmaceuticals Inc
OTC:ELTP
Price:
0.4
USD
2.51%
Market Closed
Market Cap:
$429.8m
Income Statement
Earnings Waterfall
Elite Pharmaceuticals Inc
Elite Pharmaceuticals Inc
Income Statement
Elite Pharmaceuticals Inc
Elite Pharmaceuticals Inc
Currency: USD
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
|
| Revenue |
9
N/A
|
12
+37%
|
14
+20%
|
18
+25%
|
22
+23%
|
25
+12%
|
26
+4%
|
25
-2%
|
25
-2%
|
26
+5%
|
29
+11%
|
32
+11%
|
33
+2%
|
41
+23%
|
41
+1%
|
34
-16%
|
43
+26%
|
41
-5%
|
47
+15%
|
57
+20%
|
66
+17%
|
71
+7%
|
70
-2%
|
84
+20%
|
105
+25%
|
123
+17%
|
140
+14%
|
|
| Gross Profit | ||||||||||||||||||||||||||||
| Cost of Revenue |
(5)
|
(8)
|
(8)
|
(10)
|
(13)
|
(13)
|
(13)
|
(14)
|
(12)
|
(13)
|
(16)
|
(17)
|
(18)
|
(21)
|
(20)
|
(18)
|
(22)
|
(21)
|
(26)
|
(30)
|
(36)
|
(39)
|
(39)
|
(44)
|
(47)
|
(58)
|
(69)
|
|
| Gross Profit |
4
N/A
|
4
+14%
|
6
+48%
|
8
+32%
|
10
+21%
|
12
+24%
|
12
+4%
|
12
-5%
|
12
+5%
|
13
+1%
|
13
+5%
|
15
+12%
|
15
+3%
|
20
+29%
|
21
+5%
|
17
-19%
|
21
+29%
|
20
-8%
|
22
+11%
|
26
+22%
|
30
+14%
|
32
+6%
|
31
-3%
|
40
+30%
|
59
+47%
|
65
+10%
|
72
+11%
|
|
| Operating Income | ||||||||||||||||||||||||||||
| Operating Expenses |
(12)
|
(10)
|
(9)
|
(10)
|
(10)
|
(10)
|
(11)
|
(10)
|
(9)
|
(9)
|
(9)
|
(10)
|
(10)
|
(14)
|
(15)
|
(13)
|
(16)
|
(14)
|
(15)
|
(16)
|
(15)
|
(15)
|
(19)
|
(19)
|
(21)
|
(23)
|
(21)
|
|
| Selling, General & Administrative |
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(7)
|
(8)
|
(5)
|
(7)
|
(5)
|
(6)
|
(7)
|
(8)
|
(8)
|
(9)
|
(9)
|
(11)
|
(12)
|
(12)
|
|
| Research & Development |
(8)
|
(6)
|
(4)
|
(6)
|
(5)
|
(6)
|
0
|
(5)
|
(4)
|
(4)
|
(5)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(7)
|
(8)
|
(8)
|
(7)
|
(8)
|
(7)
|
(8)
|
(8)
|
(7)
|
(7)
|
(6)
|
|
| Depreciation & Amortization |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(8)
N/A
|
(6)
+26%
|
(3)
+53%
|
(2)
+22%
|
(0)
+87%
|
1
N/A
|
2
+21%
|
2
+17%
|
3
+55%
|
3
+3%
|
4
+25%
|
5
+22%
|
5
+1%
|
6
+13%
|
6
+2%
|
4
-33%
|
5
+33%
|
5
-3%
|
7
+37%
|
11
+55%
|
15
+37%
|
16
+11%
|
12
-26%
|
21
+74%
|
37
+77%
|
42
+13%
|
50
+19%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||
| Interest Income Expense |
1
|
(0)
|
(4)
|
(1)
|
(4)
|
(1)
|
3
|
1
|
2
|
2
|
1
|
1
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(3)
|
(6)
|
(6)
|
(9)
|
(19)
|
(29)
|
(20)
|
(39)
|
(18)
|
5
|
|
| Non-Reccuring Items |
0
|
0
|
1
|
0
|
0
|
0
|
(1)
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(5)
|
(6)
|
(6)
|
(4)
|
(1)
|
0
|
(0)
|
0
|
0
|
|
| Pre-Tax Income |
(8)
N/A
|
(7)
+12%
|
(7)
+7%
|
(2)
+66%
|
(2)
-7%
|
2
N/A
|
6
+229%
|
4
-26%
|
6
+34%
|
5
-12%
|
5
+6%
|
6
+23%
|
5
-19%
|
5
+1%
|
6
+14%
|
4
-32%
|
5
+33%
|
1
-86%
|
(2)
N/A
|
0
N/A
|
0
-97%
|
(7)
N/A
|
(17)
-156%
|
(0)
+100%
|
(1)
-2 710%
|
24
N/A
|
55
+133%
|
|
| Net Income | ||||||||||||||||||||||||||||
| Tax Provision |
0
|
1
|
1
|
(0)
|
1
|
1
|
1
|
1
|
0
|
(0)
|
(0)
|
2
|
0
|
2
|
2
|
(0)
|
(1)
|
17
|
18
|
20
|
20
|
0
|
(1)
|
(4)
|
(9)
|
(10)
|
(12)
|
|
| Income from Continuing Operations |
(7)
|
(6)
|
(6)
|
(2)
|
(1)
|
3
|
7
|
5
|
6
|
5
|
5
|
8
|
7
|
7
|
8
|
4
|
5
|
18
|
16
|
20
|
20
|
(6)
|
(18)
|
(4)
|
(11)
|
14
|
43
|
|
| Net Income (Common) |
(7)
N/A
|
(6)
+14%
|
(6)
+8%
|
(2)
+62%
|
(1)
+36%
|
3
N/A
|
7
+147%
|
5
-22%
|
6
+26%
|
6
-11%
|
6
+5%
|
9
+49%
|
7
-23%
|
7
+0%
|
8
+10%
|
4
-53%
|
5
+32%
|
18
+279%
|
16
-13%
|
20
+29%
|
20
-3%
|
(6)
N/A
|
(18)
-182%
|
(4)
+76%
|
(11)
-151%
|
14
N/A
|
43
+212%
|
|
| EPS (Diluted) |
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0
N/A
|
0
N/A
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
-0.01
N/A
|
-0.02
-100%
|
0
N/A
|
-0.01
N/A
|
0.01
N/A
|
0.04
+300%
|
|
Switch to:
Switch to:
See Also
Discover More
